BEGIN:VCALENDAR
PRODID:-//github.com/rianjs/ical.net//NONSGML ical.net 4.0//EN
VERSION:2.0
BEGIN:VEVENT
DESCRIPTION:The cell and gene therapy sector is accelerating faster than t
 he systems designed to pay for it. With 39 FDA approved CGTs and more tha
 n 80 expected by 2032\, the widening gap between scientific progress and 
 pricing\, policy\, and reimbursement frameworks is threatening real world
  patient access. At the same time\, the last year has brought major chang
 es\, from the Cell and Gene Therapy Access Model and outcomes based agree
 ments to rising concerns about coverage and the policy changes still to c
 ome.\n\nReturning to Washington DC\, the 3rd Cell and Gene Therapy Pricin
 g and Reimbursement Summit is the only meeting built specifically for cel
 l and gene therapy biopharma\, commercial and government payers\, policym
 akers\, and healthcare providers to confront these challenges head on. Th
 rough exclusive case studies from newly commercialized companies\, deep d
 ives into the latest policy shifts\, and practical frameworks for value c
 ommunication\, you’ll gain the insights needed to navigate the current co
 mmercialization landscape and be part of the conversation discussing what
  policy changes will be needed next.\n\nJoin the stakeholders defining th
 e future of cell and gene therapy affordability\, and leave with the stra
 tegies to secure coverage\, expand treatment capacity\, and unlock patien
 t access in 2026 and beyond.\n\nURLs:Website: https://go.evvnt.com/356141
 4-0?pid=185Tickets: https://go.evvnt.com/3561414-2?pid=185Brochure: https
 ://go.evvnt.com/3561414-3?pid=185\n\nDate and Time: On Tue\, 14 Jul 2026 
 08:00 - Thu\, 16 Jul 2026 16:00\n\nVenue Details: Le Meridien Washington\
 , D.C.\, The Madison\, 1177 15th Street Northwest\, Washington\, District
  of Columbia\, 20005\, United States\n\nCategory: Conferences | Science\,
  Health and Medicine | Pharmaceuticals | Regulatory Affairs\n\nPrices:Dru
 g Developer Pricing - Conference + 2 Workshops: USD 4397.00\,Drug Develop
 er Pricing - Conference + 1 Workshops: USD 3748.00\,Drug Developer Pricin
 g - Conference Only: USD 3099.00\,Academic and Research Institutes - Conf
 erence + 2 Workshops: USD 3797.00\,Academic and Research Institutes - Con
 ference + 1 Workshops: USD 3248.00\,Academic and Research Institutes - Co
 nference Only: USD 2699.00\,Solution and Service Providers - Conference +
  2 Workshops: USD 5297.00\,Solution and Service Providers - Conference + 
 1 Workshops: USD 4548.00\,Solution and Service Providers - Conference Onl
 y: USD 3799.00\n\nSpeakers: Jon Weber\, Senior Director Cell and Gene The
 rapy Market Access Lead\, Bayer\, Jamie Gibfried\, Senior Director US Cel
 l Therapy Access Strategy\, Bristol Myers Squibb\, Jillian Fahey\, Execut
 ive Director Cell Therapy Patient Access and Field Reimbursement\, Bristo
 l Myers Squibb\, Arielle Gurwitch\, Senior Director US Public Policy\, El
 i Lilly\, Laura Okpala\, Executive Director and Head of Reimbursement Pol
 icy and Government Affairs\, Gilead Sciences\, Vadi Shahid\, Director Pay
 ment and Health Care Delivery Policy\, Johnson and Johnson\, Brad Berigan
 \, Senior Director and Head of Market Access Strategic Account Engagement
 \, Kite Pharma\, Mark Prygoda\, Senior Director US Market Access Strategy
  and Operations\, Autolus\, Ravi Singh\, Vice President Market Access\, A
 dvocacy and Policy\, Genetix Biotherapeutics\, Jodie Wehling\, Vice Presi
 dent Market Access and Head of Market Access\, Trade and Distribution\, M
 esoblast\, Carrie Edwards\, Wolkoff Director\, Government Account\, MACs\
 , MCD\, VA/ DOD\, Neurotech Pharmaceuticals\, Kimberly Burlison\, Head US
  Market Access\, Orchard Therapeutics\, David Davenport\, Director US Pol
 icy\, Alliance for Regenerative Medicine\, Marianne Hamilton Lopez\, Seni
 or Research Director Biomedical Innovation\, Duke-Margolis Center for Hea
 lth Policy\, Taylor Hittle\, Executive Director\, Partnership for Employe
 r-Sponsored Coverage\, Mark Trusheim\, Senior Strategy Advisor NEWDIGS\, 
 Tufts Medical Center\, Paul Eiting\, Managing Director Legislative and Re
 gulatory Policy\, Blue Cross Blue Shield Association\, Eugean Jiwanmall\,
  Lead Research Analyst for Medical Policy and Health Technology Evaluatio
 n\, Independence Blue Cross Family of Companies and Independence Health G
 roup\, Terry Cothran\, Chief Pharmacy Officer\, Oklahoma Health Care Auth
 ority\, Michael Byrne\, Medical Director Cellular Therapy\, OneOncology\,
  Chad Bissell\, Vice President Drug Launch Services and Clinical Operatio
 ns\, Artia Solutions - Powered by Petauri\n
DTEND:20260716T160000
DTSTAMP:20260512T220334Z
DTSTART:20260714T080000
LOCATION:Le Meridien Washington\, D.C.\, The Madison\, 1177\, 15th Street 
 Northwest\, Washington\, District of Columbia\, 20005\,
SEQUENCE:0
SUMMARY:The cell and gene therapy sector is accelerating faster than the s
 ystems designed to pay for it. With 39 FDA approved CGTs and more than 80
  expecte...
UID:23d6114a-a22d-4b06-b097-c6a8ac541501
END:VEVENT
END:VCALENDAR